Evaluation of Two Intraoperative Gamma Detectors for Assessment of Lu Activity Concentration in Vivo

Overview

Journal EJNMMI Phys

Specialty Radiology

Date 2017 Jan 11

PMID 28070731

Citations 1

Authors

Viktor Sandblom

Ingun Stahl

Roger Olofsson Bagge

Eva Forssell-Aronsson

Affiliations

Soon will be listed here.

Abstract

Background: Patients with somatostatin receptor-expressing neuroendocrine tumours can be treated with intravenously administered Lu-octreotate. Few patients are cured with the present protocol due to the current dose limitation of normal organs at risk, such as the kidneys. By locally administering Lu-octreotate to the liver for the purpose of treating liver metastases, a substantially reduced absorbed dose to organs at risk could be achieved. The development of such a technique requires the capability of measuring the Lu activity concentration in tissues in vivo. The aim of this study was to evaluate different performance parameters of two commercially available intraoperative gamma detectors in order to investigate whether intraoperative gamma detector measurements could be used to determine Lu activity concentration in vivo.

Results: Measurements were made using different sources containing Lu. Response linearity, sensitivity, spatial resolution and its depth dependence, organ thickness dependence of the measured count rate and tumour detectability were assessed for two intraoperative gamma detectors. The two detectors (a scintillation and a semiconductor detector) showed differences in technical performance. For example, the sensitivity was higher for the scintillation detector, while the spatial resolution was better for the semiconductor detector. Regarding organ thickness dependence and tumour detectability, similar results were obtained for both detectors, and even relatively small simulated tumours of low tumour-to-background activity concentration ratios could be detected.

Conclusions: Acceptable results were obtained for both detectors, although the semiconductor detector proved more advantageous for our purpose. The measurements demonstrated factors that must be corrected for, such as organ thickness or dead-time effects. Altogether, intraoperative gamma detector measurements could be used to determine Lu activity concentration in vivo.

Citing Articles

Feasibility of Lu activity quantification using a small portable CZT-based gamma-camera.

Roth D, Larsson E, Strand J, Ljungberg M, Sjogreen Gleisner K EJNMMI Phys. 2024; 11(1):2.

PMID: 38167976 PMC: 10761658. DOI: 10.1186/s40658-023-00602-2.

References

Schirmer W, ODorisio T, Schirmer T, Mojzisik C, Hinkle G, Martin E . Intraoperative localization of neuroendocrine tumors with 125I-TYR(3)-octreotide and a hand-held gamma-detecting probe. Surgery. 1993; 114(4):745-51; discussion 751-2. View

Benjegard S, Sauret V, Bernhardt P, Wangberg B, Ahlman H, Forssell-Aronsson E . Evaluation of three gamma detectors for intraoperative detection of tumors using 111In-labeled radiopharmaceuticals. J Nucl Med. 2000; 40(12):2094-101. View

Valkema R, Pauwels S, Kvols L, Kwekkeboom D, Jamar F, de Jong M . Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005; 46 Suppl 1:83S-91S. View

Povoski S, Neff R, Mojzisik C, OMalley D, Hinkle G, Hall N . A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol. 2009; 7:11. PMC: 2653072. DOI: 10.1186/1477-7819-7-11. View

Britten A . A method to evaluate intra-operative gamma probes for sentinel lymph node localisation. Eur J Nucl Med. 1999; 26(2):76-83. DOI: 10.1007/s002590050362. View

Wangberg B, Forssell-Aronsson E, Tisell L, Nilsson O, Fjalling M, Ahlman H . Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br J Cancer. 1996; 73(6):770-5. PMC: 2074371. DOI: 10.1038/bjc.1996.134. View

Bonjer H, Bruining H, Pols H, de Herder W, van Eijck C, Breeman W . Intraoperative nuclear guidance in benign hyperparathyroidism and parathyroid cancer. Eur J Nucl Med. 1997; 24(3):246-51. DOI: 10.1007/BF01728759. View

Tuttle S, Jewell S, Mojzisik C, Hinkle G, Colcher D, Schlom J . Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization. Int J Cancer. 1988; 42(3):352-8. DOI: 10.1002/ijc.2910420308. View

Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M . [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010; 34(6):1368-72. DOI: 10.1007/s00268-009-0387-6. View

10.

Curtet C, Vuillez J, Daniel G, Aillet G, Chetanneau A, Visset J . Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody. Eur J Nucl Med. 1990; 17(6-8):299-304. DOI: 10.1007/BF01268019. View

11.

Heller S, Zanzonico P . Nuclear probes and intraoperative gamma cameras. Semin Nucl Med. 2011; 41(3):166-81. DOI: 10.1053/j.semnuclmed.2010.12.004. View

12.

Benjegard S, Forssell-Aronsson E, Wangberg B, Skanberg J, Nilsson O, Ahlman H . Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. Eur J Nucl Med. 2001; 28(10):1456-62. DOI: 10.1007/s002590100600. View

13.

Svensson J, Molne J, Forssell-Aronsson E, Konijnenberg M, Bernhardt P . Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice. Nucl Med Biol. 2012; 39(6):756-62. DOI: 10.1016/j.nucmedbio.2012.02.003. View

14.

Forssell-Aronsson E, Bernhardt P, Nilsson O, Tisell L, Wangberg B, Ahlman H . Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol. 2004; 43(5):436-42. DOI: 10.1080/02841860410030670. View

15.

Ahlman H, Wangberg B, Tisell L, Nilsson O, Fjalling M, Forssell-Aronsson E . Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg. 1994; 81(8):1144-9. DOI: 10.1002/bjs.1800810820. View

16.

Gillams A, Cassoni A, Conway G, Lees W . Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005; 30(4):435-41. DOI: 10.1007/s00261-004-0258-4. View

17.

Skanberg J, Ahlman H, Fjalling M, Forssell-Aronsson E, Hashemi S, Nilsson O . Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer. Breast Cancer Res Treat. 2002; 74(2):101-11. DOI: 10.1023/a:1016120529858. View

18.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

19.

Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti M, Conte D . Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008; 14(35):5377-84. PMC: 2744160. DOI: 10.3748/wjg.14.5377. View

20.

Bolch W, Eckerman K, Sgouros G, Thomas S . MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009; 50(3):477-84. DOI: 10.2967/jnumed.108.056036. View